Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017168 (gastroesophageal reflux disease)
 11,783 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Cisapride is a new drug which stimulates gastrointestinal motility via facilitation of acetylcholine release from myenteric nerves. European studies have addressed its clinical efficacy in treating gastro-oesophageal reflux disease in three areas. 1) Symptom relief: Cisapride, usually at a dose of 10 mg t.i.d., was superior to placebo and metoclopramide in relief of daytime and night-time heartburn and regurgitation. 2) Healing oesophagitis: Six studies showed that cisapride 10 mg q.i.d effectively heals oesophagitis over 6-16 weeks. Cisapride was superior to placebo and as effective as H2-antagonists in healing grades I-III oesophagitis. Combination therapy with H2-antagonists may be superior to H2-blocker alone. 3) Paediatric efficacy: Cisapride 1 mg/kg/day was effective in the treatment of infants and children with oesophagitis and pulmonary symptoms related to acid reflux. In conclusion, cisapride offers a promising alternative for the treatment of gastrooesophageal reflux disease without the troubling side effects of existing promotility drugs.
 ...
PMID:Efficacy of cisapride on symptoms and healing of gastro-oesophageal reflux disease: a review. 269 Mar 21

Inflammatory lesions involving esophagus, stomach and duodenum are frequent in neonates and run a benign course. Thirty-two cases of esophagogastritis associated with duodenitis in 28% of cases were studied. Presenting symptoms included nonspecific symptoms such as feeding difficulties (15 cases), G-I bleeding (14 cases), regurgitation (14 cases) and/or impaired weight gain (4 cases). No precipitating factor could be identified. The diagnosis was established by endoscopy. Gastro-esophageal reflux, which seemed to be secondary to the mucosal lesions, required an anti-reflux treatment, which led to a rapid clinical recovery. Repeat endoscopy invariably showed an improvement or complete recovery of the mucosal lesions which did not seem to be influenced by antacid treatment. The etiology and pathogenesis of neonatal esophagogastroduodenitis remain undetermined.
 ...
PMID:[Esophagogastroduodenitis in the newborn. Apropos of 32 cases]. 269 94

Chalasia, the regurgitation of gastric contents into the esophagus, is a common problem seen in infancy. In some cases, however, the symptoms can be more complex and extend beyond early infancy. In these infants and children, the pathologic condition of gastroesophageal reflux may exist. It can be a challenge to assess whether these patients require further investigation and treatment. This article outlines the difference between simple chalasia and pathologic gastroesophageal reflux. Information is given that enables the clinician to provide children and families anticipatory guidance regarding the medical workup and management of this problem. In addition, the article provides clinical algorithms to enhance the practitioner's understanding of the decision-making process involved in treating these patients.
 ...
PMID:Assessing children with chalasia: rule out gastroesophageal reflux. 277 Dec 8

Clinical signs of esophageal hiatal hernia in four dogs and one cat included regurgitation, vomiting, hematemesis, hypersalivation, dysphagia, and dyspnea. Thoracic radiographs, esophagram, and fluoroscopy were used to demonstrate cranial displacement of the esophagogastric junction and part of the stomach through the esophageal hiatus. Other findings included megaesophagus, esophageal hypomotility, gastroesophageal reflux, and pneumonia. Medical therapy failed to resolve the clinical signs. Reduction in size of the esophageal hiatus, fixation of the esophagus to the diaphragmatic crus (esophagopexy), and a left fundic gastropexy were performed. Surgical results were considered good to excellent.
 ...
PMID:Hiatal hernia repair by restoration and stabilization of normal anatomy. An evaluation in four dogs and one cat. 281 56

Symptomatic gastroesophageal reflux occurs daily in an estimated 7% of adults and weekly or monthly in 29%. Untreated it can lead to esophageal erosions, ulceration and stricture formation. The pathogenesis is often multifactorial: defects in the function of the lower esophageal sphincter, esophageal clearance mechanisms and gastric emptying combine to produce frequent lengthy periods during which the lower esophagus is bathed in regurgitated acid. In most patients reflux disease is easily recognized as recurrent heartburn, regurgitation or dysphagia, or a combination. When acute chest pain or respiratory illness is the primary presenting complaint the patient needs particularly careful investigation to determine whether the symptoms are due to a primary cardiac or respiratory condition, are secondary to gastroesophageal reflux alone or represent a combination of disorders. Endoscopy with biopsy and long-term pH monitoring are the most reliable ways of determining whether reflux disease is present. Additional investigations, such as exercise testing, cardiac catheterization or inhalation challenge, may be needed in patients with cardiac or respiratory symptoms. Treatment should follow a stepped-care approach and in most patients should begin with changes in lifestyle, including dietary manipulation, reducing alcohol and cigarette consumption, and raising the head of the bed, together with appropriate use of antacids or alginate-antacid combinations. H2-receptor antagonists and agents to improve both gastric emptying and the tone of the lower esophageal sphincter may be added in sequence. Most patients will respond well to this regimen. Surgery should be considered only for those with intractable symptoms or with complications (e.g., stricture formation, bleeding, development of dysplastic epithelium in those with Barrett's esophagus, or secondary pulmonary disease that does not respond to medical management). It is successful in 85% of well-selected patients and has few complications.
 ...
PMID:Gastroesophageal reflux: clinical presentations, diagnosis and management. 287 69

We studied 76 patients with symptoms of heartburn, regurgitation, or both and 38 asymptomatic control subjects by measuring the gastric emptying of technetium-99m-labeled oatmeal. In addition, we performed 24-hour esophageal pH monitoring and manometric studies of the esophagus on all study participants. Endoscopy was performed on all patients. Patients with proved reflux on 24-hour pH monitoring, in comparison to those without reflux and the control subjects, had a shorter lower esophageal segment with a lower pressure and more esophagitis. Delayed gastric emptying occurred with equal frequency in patients with and without reflux. Esophageal reflux was not associated with delayed gastric emptying. Delayed emptying was associated with less esophagitis than found in those with normal gastric emptying, suggesting that the prolonged presence of food in the stomach may have a buffering effect on gastric acidity. We concluded that delayed emptying is not a major factor in the pathophysiology of gastro-esophageal reflux disease and that therapy aimed at speeding gastric emptying cannot be supported by our results.
 ...
PMID:Does delayed gastric emptying contribute to gastroesophageal reflux disease? 291 Jan 30

We studied the effects of an alginate compound (Gaviscon) on the frequency and the duration of gastroesophageal reflux (GOR) episodes in children. Twenty infants and children with characteristic symptoms of GOR were divided at random into two groups which were given either Gaviscon (ten patients, mean age: 21 months) or a placebo (ten patients, mean age: 35 months). A continuous pH probe monitoring of the lower oesophageal third was performed in all the patients before and after 8 days of treatment. Before the trial, sensitive pH monitoring variables of acid reflux (Euler-Byrne index, percentage of total reflux time per 24 h, mean duration and percentage of reflux time during sleep, total number of reflux episodes per 24 h and number of reflux episodes per 2 h post-cibal periods) were abnormal in all the patients tested. The oesophagram revealed a GOR in 13 of the 20 patients; none of the children who underwent an endoscopy had evidence of oesophagitis. Episodes of regurgitation reported by the parents decreased during Gaviscon therapy while no clinical improvement was noticed in the placebo group. No adverse effects were observed. After 8 days of treatment with Gaviscon, results of all the pH monitoring variables were significantly (P less than 0.05) reduced between -35% and -61% of the initial values recorded. In the placebo treated group, the mean values remained little changes (-9.5 to +8.2% of initial values). These data suggest that Gaviscon may prove useful in the medical management of GOR in infants and children.
 ...
PMID:Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. 303 40

The aetiologic factors in gastro-oesophageal reflux disease include the free reflux of gastric juice, the composition of refluxed juice, the defensive mechanisms of the oesophagus, which are both mechanical and mucosal, and, sometimes, gastric abnormalities. Symptoms include heartburn, odynophagia, chest pain, dysphagia, regurgitation, and, occasionally, haemorrhage. Respiratory symptoms may occur. Diagnosis is based on determining the pressure and frequency of reflux (for which pH monitoring is preferred), testing for symptoms that may be caused by reflux, and assessing the degree of oesophagitis, for which endoscopy and histology are the only known techniques.
 ...
PMID:Aetiology, pathogenesis, and clinical manifestations of gastro-oesophageal reflux disease. 306 36

In a double-blind, randomized study, the clinical effects of 5 mg and 10 mg of cisapride three times daily were compared with those of 10 mg of metoclopramide three times daily in 114 patients with symptoms of gastroesophageal reflux, mainly diurnal and nocturnal heartburn and regurgitation. The symptoms significantly (P less than 0.001) improved in the three groups; the mean severity score decreased by at least 78% after four weeks of treatment. Initial symptoms were more severe in the cisapride-treated patients, especially in those receiving 10 mg three times daily; however, the patients' condition after four weeks was similar in the three groups. Central nervous system side effects were reported by one patient from each of the cisapride-treated groups and by nine of the 43 metoclopramide-treated patients (P less than 0.02). Six metoclopramide-treated patients and one cisapride-treated patient dropped out of the study because of side effects. These findings favor the use of cisapride when prokinetic treatment of gastroesophageal reflux is considered.
 ...
PMID:Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease. 307 10

Enteral nutrition is a safe technique but complications may arise. Mechanical problems can occur as a result of tube malposition: regurgitation can induce respiratory distress. Esophagitis is rare and does not seem to be related to acid gastro-oesophageal reflux. Diarrhea, the main gastro-intestinal side effect, has a complex etiology; management requires knowledge of gastro-intestinal physiology during enteral nutrition. Many of the problems encountered with enteral feeding can be avoided by using a fine bore tube, administering the feed by continuous infusion, and careful monitoring of patients for metabolic abnormalities.
 ...
PMID:[Digestive and respiratory complications in enteral nutrition]. 314 96


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>